Lexaria Bioscience Corp’s (NASDAQ:LEXX, LEXXW) proprietary drug delivery-enabling technology, DehydraTECH™, improves the absorption of active pharmaceutical ingredients (APIs) into the bloodstream, allowing greater drug effectiveness often with reduced side effects.
DehydraTECH is a platform technology that can be applied to many different APIs and other bioactive substances, spanning both small and large molecule therapeutics, in oral formats including tablets, capsules, oral suspensions and more.
- Increases bloodstream absorption of therapeutics taken orally
- Reduces time of onset from up to 1 – 2 hours to as little as just minutes
- Often reduces adverse events
- Shown to increase drug delivery into brain tissue for therapeutics that act upon the central nervous system
- Shown in early clinical testing to achieve better absorption and blood sugar control of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide relative to the established commercial comparator
Companies in various locations around the world are examining DehydraTECH for incorporation into a broad range of drug and consumer products. Lexaria operates a federally licensed, in-house formulation development and research laboratory and is building a robust intellectual property portfolio with 46 patents granted internationally and many more patents pending worldwide.
